PDCD1 and neoplasm: Herein, we describe the efficacy of anti-PD1 immunotherapy both as a monotherapy and as an adjunct to primary radiation in a murine model of cSCC, as well as the impact of combining radiation with anti-PD1 immunotherapy in this tumor model.